The CAB will lead and advise Genprex as it advances its REQORSA immunogen therapy program, including its Acclaim clinical trials in non-small cell lung...
New research could help transform treatment options for the 1.2 million Australians affected by type 2 diabetes.An Australian study is asking patients to enroll...